MedTrace Logo

Clinical Study of KD6001 in Advanced Solid Tumours

NCT05230290 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2023-02-06

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability and clinical activity of KD6001 as treatment for participants with advanced solid tumours.

Conditions

Interventions

BIOLOGICAL

KD6001 Injection

Solution for intravenous injection

Sponsors & Collaborators

  • Shanghai Kanda Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jun Guo, MD · Peking University Cancer Hospital & Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-10
Primary Completion
2022-07-20
Completion
2022-07-26

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05230290 on ClinicalTrials.gov